TiumBio Co., Ltd.
Research TiumBio Co., Ltd. (321550.KQ) on Bullrun: market cap KRW 121.96B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker321550.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 121.96B
- Financial periodQ2 2026
- RevenueKRW 4.48B
- Net income-KRW 4.30B
- Free cash flow-KRW 4.22B
- Gross margin43.2%
Valuation Snapshot
latest market cap is KRW 121.96B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 121.96B | n/a | n/a | n/a |
Dividend history
About TiumBio Co., Ltd.
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TiumBio Co., Ltd.'s market cap?
TiumBio Co., Ltd.'s market capitalization is KRW 121.96B.
What does TiumBio Co., Ltd. do?
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea.